Telithromycin
Authors: Michelle Turner, G. Ralph Corey, Elias Abrutyn
Journal: Annals of Internal Medicine (2006)

Editorials21 March 2006TelithromycinMichelle Turner, PharmD, G. Ralph Corey, MD, and Elias Abrutyn, MDMichelle Turner, PharmDFrom Campbell University School of Pharmacy and Duke University Medical Center, Durham, NC 27710; Duke Clinical Research Institute, Durham, NC 27710; and Drexel University College of Medicine, Philadelphia, PA 19102-1192., G. Ralph Corey, MDFrom Campbell University School of Pharmacy and Duke University Medical Center, Durham, NC 27710; Duke Clinical Research Institute, Durham, NC 27710; and Drexel University College of Medicine, Philadelphia, PA 19102-1192., and Elias Abrutyn, MDFrom Campbell University School of Pharmacy and Duke University Medical Center, Durham, NC 27710; Duke Clinical Research Institute, Durham, NC 27710; and Drexel University College of Medicine, Philadelphia, PA 19102-1192.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-144-6-200603210-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Elsewhere in this issue, Clay and colleagues (1) describe a serious adverse event related to telithromycin. This report should cause physicians who prescribe telithromycin to pause in order to be sure it is the right antibiotic for the circumstances. Herein we provide information about telithromycin to help clinicians decide when to prescribe it.Telithromycin (Ketek, Aventis Pharmaceuticals, Bridgewater, New Jersey), the first marketed ketolide antibiotic, is a modification of the macrolide structure. Like macrolides (2), telithromycin blocks protein synthesis (3). However, compared with macrolides, it has increased affinity for the binding sites on domains II and V of the 50S ...References1. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144:415-20. LinkGoogle Scholar2. Zuckerman JM. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am. 2004;18:621-49. [PMID: 15308279] CrossrefMedlineGoogle Scholar3. Product Information: Ketek [Telithromycin]. Kansas City, MO: Aventis Pharmaceuticals Inc; 10 2005. Google Scholar4. Novotny GW, Jakobsen L, Andersen NM, Poehlsgaard J, Douthwaite S. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob Agents Chemother. 2004;48:3677-83. [PMID: 15388419] CrossrefMedlineGoogle Scholar5. Low DE, Felmingham D, Brown SD, Rangaraju M, Nusrat R. Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections. J Infect. 2004;49:115-25. [PMID: 15236918] CrossrefMedlineGoogle Scholar6. Walsh F, Carnegy F, Willcock J, Amyes S. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother. 2004;53:793-6. [PMID: 15056640] CrossrefMedlineGoogle Scholar7. Hammerschlag MR, Roblin PM, Bebear CM. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. J Antimicrob Chemother. 2001;48 Suppl T1 25-31. [PMID: 11566973] CrossrefMedlineGoogle Scholar8. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44:915-34. [PMID: 16122280] CrossrefMedlineGoogle Scholar9. Ong CT, Dandekar PK, Sutherland C, Nightingale CH, Nicolau DP. Intrapulmonary concentrations of telithromycin: clinical implications for respiratory tract infections due to Streptococcus pneumoniae. Chemotherapy. 2005;51:339-46. [PMID: 16224186] CrossrefMedlineGoogle Scholar10. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002;30:378-86. [PMID: 12478329] CrossrefMedlineGoogle Scholar11. Van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin. 2002;18:397-400. [PMID: 12487505] CrossrefMedlineGoogle Scholar12. Pullman J, Champlin J, Vrooman PS. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract. 2003;57:377-84. [PMID: 12846341] MedlineGoogle Scholar13. Roos K, Brunswig-Pitschner C, Kostrica R, Pietola M, Leroy B, Rangaraju M, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002;48:100-8. [PMID: 12011543] CrossrefMedlineGoogle Scholar14. Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J. 2003;82:576-80, 82-4, 586 passim. [PMID: 14503094] Google Scholar15. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol. 2003;17:369-77. [PMID: 14750614] CrossrefMedlineGoogle Scholar16. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002;96:862-71. [PMID: 12418583] CrossrefMedlineGoogle Scholar17. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res. 2003;31:157-69. [PMID: 12870368] CrossrefMedlineGoogle Scholar18. Ketek FDA briefing document. Kansas City, MO: Aventis Pharmaceuticals Inc; 1 2003. Google Scholar19. Nieman RB, Sharma K, Edelberg H, Caffe SE. Telithromycin and myasthenia gravis [Letter]. Clin Infect Dis. 2003;37:1579. [PMID: 14614683] CrossrefMedlineGoogle Scholar20. Aventis Pharmaceuticals Inc. Ketek worldwide experience. Updated August 2005. Accessed at www.ketek.com/hcp/WorldwideExperience.do on 8 February 2006. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Campbell University School of Pharmacy and Duke University Medical Center, Durham, NC 27710; Duke Clinical Research Institute, Durham, NC 27710; and Drexel University College of Medicine, Philadelphia, PA 19102-1192.Disclosures: Employment: G.R. Corey (Duke University Medical Center); Consultancies: G.R. Corey (Cubist).Corresponding Author: Michelle Turner, PharmD, Duke University Medical Center, Box 3089, Durham, NC 27710.Current Author Addresses: Dr. Turner: Duke University Medical Center, Box 3089, Durham, NC 27710.Dr. Corey: Duke Clinical Research Institute, 2400 Pratt Street, Room 7030Durham, NC 27710.Dr. Abrutyn: Drexel University College of Medicine, Mailstop 441, 245 North 15th Street, Philadelphia, PA 19102-1192. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBrief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review Kimberly D. Clay , John S. Hanson , Scott D. Pope , Richard W. Rissmiller , Preston P. Purdum III , and Peter M. Banks Metrics Cited ByAdvanced Methods for Studying Structure and Interactions of Macrolide AntibioticsImaging Mass Microscopy of Kidneys from Azithromycin-Treated Rats with PhospholipidosisKetolidesANTIBACTERIAL DRUGSA Strategy for Risk Management of Drug-Induced PhospholipidosisMiscellaneous antibacterial drugsDisorders of Neuromuscular TransmissionHepatic adverse drug reactions: a case/non-case study in ItalyHepatotoxicity with Telithromycin; Sirolimus-Associated Pneumonitis; Erythema Nodosum Associated with Vaginal Ring Contraceptive; Respiratory Failure with a Single Dose of Quetiapine; Pantoprazole-Induced Thrombocytopenia in Two Patients; Pharmacist Counseling CAN Prevent Adverse Drug Events; Symposium on Anaphylaxis 21 March 2006Volume 144, Issue 6Page: 447-448KeywordsAntibiotic resistanceAntibioticsAttentionDrug administrationDrugsLiverMycoplasma pneumoniaePneumoniaUpper respiratory tract infections ePublished: 21 March 2006 Issue Published: 21 March 2006 CopyrightCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...